Corvus Pharmaceuticals, Inc. (CRVS): Nasdaq/NYSE listing notice — Corvus Pharma receives Nasdaq delisting notice for bid price below $1.00

Corvus Pharmaceuticals, Inc.

Nasdaq notified Corvus on Oct 25, 2022 that its stock failed to maintain minimum $1.00 bid price for 30 consecutive business days.
Company has 180 calendar days, until April 24, 2023, to regain compliance by closing at $1.00+ for 10 consecutive days.
If non-compliance persists, Corvus may transfer to Nasdaq Capital Market and seek an additional 180-day grace period.
Corvus may consider a reverse stock split or other options to cure the deficiency but no assurance of success.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Corvus Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

ule 5450(a)(1) (the “Minimum Bid Price Requirement”). Nasdaq’s written notice does not result in the immediate delisting

View on SEC.gov

Browse all listing & compliance notices →

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-006866

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.